Compare ECPG & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECPG | XERS |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 1999 | 2021 |
| Metric | ECPG | XERS |
|---|---|---|
| Price | $95.00 | $8.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $77.33 | $10.83 |
| AVG Volume (30 Days) | 324.4K | ★ 1.9M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 287.14 | 100.00 |
| EPS | ★ 3.86 | 0.01 |
| Revenue | ★ $1,768,802,000.00 | $49,590,000.00 |
| Revenue This Year | $4.53 | $34.37 |
| Revenue Next Year | $4.76 | $22.86 |
| P/E Ratio | ★ $24.47 | $821.00 |
| Revenue Growth | 34.37 | ★ 142.67 |
| 52 Week Low | $35.68 | $4.87 |
| 52 Week High | $94.60 | $10.08 |
| Indicator | ECPG | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 62.55 | 54.38 |
| Support Level | $77.69 | $8.00 |
| Resistance Level | N/A | $8.42 |
| Average True Range (ATR) | 3.23 | 0.33 |
| MACD | 0.05 | -0.11 |
| Stochastic Oscillator | 80.56 | 24.00 |
Encore Capital Group Inc is an international specialty finance company engaged in providing debt recovery solutions and other related services for consumers across a broad range of financial assets. It mainly purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals to repay their obligations and work toward financial recovery. The company also provides debt servicing and other portfolio management services to credit originators for non-performing loans in Europe. It has only one reportable segment, debt purchasing and recovery. Geographically, the company generates maximum revenue from its business in the United States, followed by the United Kingdom, Europe, and other regions.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.